Chemotherapy for gastric cancer

Hideo Baba, Yoshihiro Kakeji, Eiji Oki, Eriko Tokunaga, Shin Ushiro, Masayuki Watanabe, Yoshihiko Maehara

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

5-FU has been a key chemotherapeutic agent in the treatment of advanced or recurrent gastric cancer. In order to enhance the effect of 5-FU, biochemical modulation or combined chemotherapy has been developed. Although several phase III studies have been reported in 1990's, a standard chemotherapeutic regimen has not been established worldwide. Recently, newly developed anticancer agents such as CPT-11, TS-1, Paclitaxel, or Docetaxel can be clinically used for advanced gastric cancer either single agent or in combination that may further improve the quality of life and prolong the survival of patients with gastric cancer. In Japan, postoperative adjuvant chemotherapy has been actively developed to enhance survival benefit of surgery for patients with gastric cancer. There were a few positive single randomized controlled study showing benefit of adjuvant chemotherapy with a high evidence level. However, all reports of meta-analysis of adjuvant chemotherapy for gastric cancer indicated the survival benefit of adjuvant chemotherapy. At present, a nation-wide randomized controlled study in the postoperative adjuvant setting for gastric cancer using TS-1 (ACTS-GC) is under way that may clarify the effect of postoperative adjuvant chemotherapy in gastric cancer.

Original languageEnglish
Pages (from-to)1881-1888
Number of pages8
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume30
Issue number12
Publication statusPublished - Jan 1 2003

Fingerprint

Stomach Neoplasms
Adjuvant Chemotherapy
Drug Therapy
irinotecan
docetaxel
Fluorouracil
Survival
Paclitaxel
Antineoplastic Agents
Meta-Analysis
Japan
Quality of Life

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Baba, H., Kakeji, Y., Oki, E., Tokunaga, E., Ushiro, S., Watanabe, M., & Maehara, Y. (2003). Chemotherapy for gastric cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 30(12), 1881-1888.

Chemotherapy for gastric cancer. / Baba, Hideo; Kakeji, Yoshihiro; Oki, Eiji; Tokunaga, Eriko; Ushiro, Shin; Watanabe, Masayuki; Maehara, Yoshihiko.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 30, No. 12, 01.01.2003, p. 1881-1888.

Research output: Contribution to journalReview article

Baba, H, Kakeji, Y, Oki, E, Tokunaga, E, Ushiro, S, Watanabe, M & Maehara, Y 2003, 'Chemotherapy for gastric cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 30, no. 12, pp. 1881-1888.
Baba H, Kakeji Y, Oki E, Tokunaga E, Ushiro S, Watanabe M et al. Chemotherapy for gastric cancer. Gan to kagaku ryoho. Cancer & chemotherapy. 2003 Jan 1;30(12):1881-1888.
Baba, Hideo ; Kakeji, Yoshihiro ; Oki, Eiji ; Tokunaga, Eriko ; Ushiro, Shin ; Watanabe, Masayuki ; Maehara, Yoshihiko. / Chemotherapy for gastric cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2003 ; Vol. 30, No. 12. pp. 1881-1888.
@article{455c4ac9fd76416a8687b88ecaa23cc0,
title = "Chemotherapy for gastric cancer",
abstract = "5-FU has been a key chemotherapeutic agent in the treatment of advanced or recurrent gastric cancer. In order to enhance the effect of 5-FU, biochemical modulation or combined chemotherapy has been developed. Although several phase III studies have been reported in 1990's, a standard chemotherapeutic regimen has not been established worldwide. Recently, newly developed anticancer agents such as CPT-11, TS-1, Paclitaxel, or Docetaxel can be clinically used for advanced gastric cancer either single agent or in combination that may further improve the quality of life and prolong the survival of patients with gastric cancer. In Japan, postoperative adjuvant chemotherapy has been actively developed to enhance survival benefit of surgery for patients with gastric cancer. There were a few positive single randomized controlled study showing benefit of adjuvant chemotherapy with a high evidence level. However, all reports of meta-analysis of adjuvant chemotherapy for gastric cancer indicated the survival benefit of adjuvant chemotherapy. At present, a nation-wide randomized controlled study in the postoperative adjuvant setting for gastric cancer using TS-1 (ACTS-GC) is under way that may clarify the effect of postoperative adjuvant chemotherapy in gastric cancer.",
author = "Hideo Baba and Yoshihiro Kakeji and Eiji Oki and Eriko Tokunaga and Shin Ushiro and Masayuki Watanabe and Yoshihiko Maehara",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "30",
pages = "1881--1888",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - Chemotherapy for gastric cancer

AU - Baba, Hideo

AU - Kakeji, Yoshihiro

AU - Oki, Eiji

AU - Tokunaga, Eriko

AU - Ushiro, Shin

AU - Watanabe, Masayuki

AU - Maehara, Yoshihiko

PY - 2003/1/1

Y1 - 2003/1/1

N2 - 5-FU has been a key chemotherapeutic agent in the treatment of advanced or recurrent gastric cancer. In order to enhance the effect of 5-FU, biochemical modulation or combined chemotherapy has been developed. Although several phase III studies have been reported in 1990's, a standard chemotherapeutic regimen has not been established worldwide. Recently, newly developed anticancer agents such as CPT-11, TS-1, Paclitaxel, or Docetaxel can be clinically used for advanced gastric cancer either single agent or in combination that may further improve the quality of life and prolong the survival of patients with gastric cancer. In Japan, postoperative adjuvant chemotherapy has been actively developed to enhance survival benefit of surgery for patients with gastric cancer. There were a few positive single randomized controlled study showing benefit of adjuvant chemotherapy with a high evidence level. However, all reports of meta-analysis of adjuvant chemotherapy for gastric cancer indicated the survival benefit of adjuvant chemotherapy. At present, a nation-wide randomized controlled study in the postoperative adjuvant setting for gastric cancer using TS-1 (ACTS-GC) is under way that may clarify the effect of postoperative adjuvant chemotherapy in gastric cancer.

AB - 5-FU has been a key chemotherapeutic agent in the treatment of advanced or recurrent gastric cancer. In order to enhance the effect of 5-FU, biochemical modulation or combined chemotherapy has been developed. Although several phase III studies have been reported in 1990's, a standard chemotherapeutic regimen has not been established worldwide. Recently, newly developed anticancer agents such as CPT-11, TS-1, Paclitaxel, or Docetaxel can be clinically used for advanced gastric cancer either single agent or in combination that may further improve the quality of life and prolong the survival of patients with gastric cancer. In Japan, postoperative adjuvant chemotherapy has been actively developed to enhance survival benefit of surgery for patients with gastric cancer. There were a few positive single randomized controlled study showing benefit of adjuvant chemotherapy with a high evidence level. However, all reports of meta-analysis of adjuvant chemotherapy for gastric cancer indicated the survival benefit of adjuvant chemotherapy. At present, a nation-wide randomized controlled study in the postoperative adjuvant setting for gastric cancer using TS-1 (ACTS-GC) is under way that may clarify the effect of postoperative adjuvant chemotherapy in gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=0642364481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642364481&partnerID=8YFLogxK

M3 - Review article

C2 - 14650954

AN - SCOPUS:0642364481

VL - 30

SP - 1881

EP - 1888

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -